Efficacy

From Wikipedia, the free encyclopedia
Jump to: navigation, search
This article is about use in pharmacology and medicine. For electrical engineering, see Luminous efficacy. For business, see Individual Voluntary Arrangement.

Efficacy is a term used in the practice of pharmacology and related areas of medicine that refers to both the maximum response achievable from an applied or dosed agent in research settings,[1] and to the capacity for therapeutic effect or beneficial change of a given therapeutic intervention in clinical settings.[not verified in body]

Pharmacology[edit]

Main article: Intrinsic activity

In pharmacology, efficacy (Emax) is the maximum response achievable from an applied or dosed agent, for instance, a small molecule drug.[1] Intrinsic activity is a relative term that describes a drug's efficacy relative to a drug with the highest observed efficacy.[2] It is a purely descriptive term that has little or no mechanistic interpretation.

In order for a drug to have an effect, it needs to bind to its target, and then to affect the function of this target. The target of a drug is commonly referred to as a receptor, but can in general be any chemically sensitive site on any molecule found in the body. The nature of such binding can be quantified by characterising how tightly these molecules, the drug and its receptor, interact: this is known as the affinity. Efficacy, on the other hand, is a measure of the action of a drug once binding has occurred. The maximum response, Emax, will be reduced if efficacy is sufficiently low, but any efficacy greater than 20 or so gives essentially the same maximum response.

The definition of efficacy has been discussed by.[3] The only way in which absolute measures of efficacy have been obtained is by single ion channel analysis of ligand gated ion channels. It is still not possible to do this for G protein-linked receptors.

In the case of the glycine receptor and the nicotinic acetylcholine receptor (muscle type), it has been proposed by Sivilotti et al. that opening of the ion channel involves two steps after agonist is bound. Firstly a conformation change to a higher affinity (but still shut) form, followed by the conformation change from shut to open.[4][5] It was found that partial agonism results from deficiency in the first step, and that the opening and shutting steps are essentially the same for both full and partial agonists. This has been confirmed and extended by Sine and colleagues (2009).[6] The implication of this work[5] is that efficacy has to be defined by at least two equilibrium constants (or, more generally, by four rate constants).

It is the combined influence of both affinity and efficacy which will determine how effectively a drug will produced a biological effect, a property known as potency.

Medicine[edit]

In medicine, efficacy is the capacity for beneficial change (or therapeutic effect) of a given intervention (for example a drug, medical device, surgical procedure, or a public health intervention).[citation needed] Establishment of the efficacy of an intervention is often done relative other available interventions, with which it will have been compared.[citation needed] Specifically, efficacy, refers to "whether a drug demonstrates a health benefit over a placebo or other intervention when tested in an ideal situation, such as a tightly controlled clinical trial."[7] Comparisons of this type are typically made in 'explanatory' randomized controlled trials, whereas 'pragmatic' trials are used to establish the effectiveness of an intervention.[citation needed]

Effectiveness refers "how the drug works in a real-world situation," and is "often lower than efficacy because of interactions with other medications or health conditions of the patient, sufficient dose or duration of use not prescribed by the physician or followed by the patient, or use for an off-label condition that had not been tested."[7][8]

See also[edit]

References[edit]

  1. ^ a b Holford NHG & Sheiner LB (1981). "Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models". Clin. Pharmacokinet. (review). 6 (6): 429–453. PMID 7032803. 
  2. ^ Neubig, RR; Spedding, M; Kenakin, T; Christopoulos, A; International Union of Pharmacology Committee on Receptor Nomenclature and Drug, Classification (December 2003). "International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology.". Pharmacological reviews. 55 (4): 597–606. doi:10.1124/pr.55.4.4. PMID 14657418. 
  3. ^ Colquhoun D (1998). "Binding, gating, affinity and efficacy. The interpretation of structure–activity relationships for agonists and of the effects of mutating receptors". British Journal of Pharmacology. 125: 923–948. doi:10.1038/sj.bjp.0702164. PMC 1565672free to read. PMID 9846630. 
  4. ^ Burzomato V, Beato M, Groot-Kormelink P, Colquhoun D & Sivilotti LG (2004). "Single-channel behavior of heteromeric alpha1beta glycine receptors: An attempt to detect a conformational change before the channel opens" (article). Journal of Neuroscience. 24: 10924–10940. doi:10.1523/jneurosci.3424-04.2004. PMID 15574743. 
  5. ^ a b Lape R, Colquhoun D, Sivilotti L (2008). "On the nature of partial agonism in the nicotinic receptor superfamily". Nature. 454: 722–728. doi:10.1038/nature07139. PMC 2629928free to read. PMID 18633353. 
  6. ^ Mukhtasimova N, Lee WY, Wang HL, Sine SM (2009). "On the nature of partial agonism in the nicotinic receptor superfamily". Nature (letter). 459: 451–454. doi:10.1038/nature07923. 
  7. ^ a b Thaul, Susan (2012-06-25). How FDA Approves Drugs and Regulates Their Safety and Effectiveness (CRS 7-5700, R41983) (CRS Report for Congress). Washington, DC: Congressional Research Service (CRS). p. 4. Retrieved 22 March 2016. 
  8. ^ Porta, Miquel, Ed. (2008). A Dictionary of Epidemiology (5th ed.). Oxford, ENG: Oxford University Press.